In the WHO classification for diffuse gliomas, molecular diagnosis has gained importance over the years. Inclusion of specific genetic markers (especially IDH-mutation status) allows tumor classification into different diagnostic, biological, and prognostic groups. High-grade gliomas are the most common primary CNS tumors, and the prognosis of glioblastoma remains poor, with limited treatment options and a median survival of 18 to 24 months. This underscores the importance of close post-treatment evaluation of brain tumors, as imaging changes following chemoradiation may mimic disease progression, and the effects of medications like antiangiogenic drugs may not accurately reflect tumor response [
1]. …